Health · Published October 22, 2026 at 7:19 PM CDT · Updated October 24, 2026 at 9:54 AM CDT
mRNA Vaccine Cuts Melanoma Recurrence Risk by 42% in Trial
What's new
New right-leaning coverage adds details on the trial's size, phase, and the use of the vaccine alongside the immunotherapy drug Keytruda.
This story is developing. The page was updated October 24, 2026 at 9:54 AM CDT as new reports came in.
What everyone agrees on
- Moderna and Merck developed a personalized mRNA vaccine for melanoma.
- The vaccine was tested in a clinical trial involving melanoma patients.
- The trial found the vaccine reduced the risk of melanoma recurrence or death by 42% compared with standard treatment.
Each fact above was reported by outlets on the left, center and right.
How each side framed it
Left-leaning outlets · 8
Left-leaning outlets emphasized the medical significance of the results, citing specialists who called them a major advancement, and noted potential uses for other cancers. Some also mentioned that the results caused a negative reaction in company stock prices.
Center-leaning outlets · 3
Center-leaning outlets focused on the clinical data and the 42% risk reduction, with some describing the results as a potential turning point in cancer treatment and noting the drop in company shares.
Right-leaning outlets · 2
Right-leaning outlets focused on the study results and their significance for melanoma patients, with one outlet detailing trial specifics such as patient numbers, the trial phase, and the use of the vaccine alongside an immunotherapy drug.
Still disputed
- Left and center outlets mentioned a drop in Moderna and Merck's stock prices following the news; right-leaning outlets did not mention this.
- Only one right-leaning outlet specified the trial's patient count and phase, details not found in other outlets' coverage.
- Only one right-leaning outlet named the immunotherapy drug (Keytruda) used alongside the vaccine; other outlets did not specify it.
Read the original reporting
- Left ABC News mRNA cancer vaccine helps reduce chances of melanoma patients' tumors returning Free to read
- Left AP News A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning Free to read
- Left CNBC Doctors call Moderna, Merck cancer vaccine data a major advancement — despite Wall Street reaction Free to read
- Left CNN Experimental mRNA vaccine cuts risk that melanoma returns by 42% A few free articles a month
- Left NBC News Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial Free to read
- Left The Guardian (US) ‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows Free to read
- Left The New York Times Melanoma Vaccine Ushers in New Hope for Cancer Patients A few free articles a month
- Left The Washington Post Breakthrough vaccine for the deadliest skin cancer cut risk by almost half Paywall
- Center BBC News First personalised cancer vaccine cuts risk of disease returning in major trial Free to read
- Center Bloomberg Oncologists Cheer Melanoma Data Paywall
- Center Reuters Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall A few free articles a month
- Right New York Post First-of-its-kind cancer vaccine helps reduce chances of melanoma patients’ tumors returning: study Free to read
- Right The Daily Wire Personalized Cancer Vaccine Shows Promise In Major Trial Free to read
See a mistake?
A simple way to report a wrong or missing fact, with no sign-up, is coming soon. Every correction will be listed publicly.
This page was written by AI from each outlet's headline and short description, following our published rules. Always check the original reporting.